四家生物技术公司提交上市申请

huangli89327

最近有消息传出又有四家生物技术公司提交S-1进行IPO申请，而他们的预期IPO总额达到了2亿6千9百万美元左右。这四家生物技术公司分别是Tobira Therapeutics, Immune Design, Zosano Pharma和Macrocure。这是否意味着2014年又将是生物技术公司IPO的丰收年？

Tobira公司此次计划IPO额度约为6900万美元，主要用于研发一种治疗艾滋病药物cenicriviroc。Cenicriviroc目前正处于临床二期阶段。

Immune Design公司顾名思义是几家专门开发癌症免疫疗法的生物技术公司，此次Immune Design希望募集6000万美元用于其现有三种免疫疗法的临床一期研究。

Zosano Pharma是由强生公司剥离出的生物技术公司，公司的主要研究方向为骨质疏松、高血压以及偏头痛。此次他们希望募集6500万美元用于一种皮肤贴剂的开发。

最后，以色列的Macrocure公司则希望在华尔街找到合适的投资者，融资7500万美元用于开发创伤愈合治疗的细胞疗法

详细英文报道：

Four more drug developers are angling to make Wall Street debuts, lining up to raise a combined $269 million as the market for biotech IPOs has shown renewed signs of life after a tepid spring.

Tobira Therapeutics, Immune Design, Zosano Pharma andMacrocure have all handed in S-1s in hopes of going public and bankrolling their pipeline treatments. And their timing is likely no accident. The market's appetite for biotech IPOs has ebbed and flowed since the onset of last year's boom, and, after a trying respite in May, investors now seem to be all ears to convincing stories in drug development.

First up, Tobira is seeking $69 million to hit the gas on cenicriviroc (CVC), an immunomodulator with potential in liver disease and HIV. The company is gearing up to start a Phase II trial of CVC in nonalcoholic steatohepatitis (NASH), an en-vogue therapy among investors after success in the field propelled Intercept Pharmaceuticals ($ICPT) to dazzling heights earlier this year. Behind the NASH program, Tobira is working on a CVC-led fixed-dose combo for HIV type 1, and the company is mapping out a late-stage trial in that indication.

Immune Design, as its name suggests, is developing treatments that harness the power of the immune system to fight cancer, and the company wants $60 million to fund the effort. The biotech has three Phase I candidates on its roster, all developed using its platforms that create tumor-specific cytotoxic T cells. There's LV305, under investigation in 5 tumor types; G100, being developed for Merkel cell carcinoma; and CMB305, a combination of LV305 and the immunotherapy G305 that Immune Design believes may be its most promising asset.

Zosano Pharma, a Johnson & Johnson ($JNJ) spinout, is seeking $65 million to fund its work on a transdermal patch that can deliver proprietary formulations of existing drugs without the need for injections. The biotech's pipeline includes treatments for osteoperosis, severe hypoglycemia and migraine.

Finally, Israel's Macrocure is seeking $75 million to bankroll the development of cell therapies for wound care. The company's chief asset, CureXcell, works by injecting living white blood cells into a patient, and the treatment is in the midst of two Phase III studies in diabetic foot ulcers and venous leg ulcers. Macrocure expects to report out data next year and file for FDA approval in 2016.

The new offerings come just days after Ocular Therapeutix filed for an $86 million IPO and Atara Biotherapeutics put in for $50 million. Meanwhile, 7 biotechs are expected to make their market debuts this week, buoyed by a recent return to bullishness in the space. Last week, Kite Pharma ($KITE) pulled off an above-the-range debut of $128 million, and Zafgen ($ZAFG) and Ardelyx ($ARDX) made it through without having to discount their shares.